196 related articles for article (PubMed ID: 32939036)
1. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.
Xu DQ; Zhao L; Li SJ; Huang XF; Li CJ; Sun LX; Li XH; Zhang LY; Jiang ZZ
Acta Pharmacol Sin; 2021 Jul; 42(7):1080-1089. PubMed ID: 32939036
[TBL] [Abstract][Full Text] [Related]
2. A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1.
Xu D; Zhao L; Jiang J; Li S; Sun Z; Huang X; Li C; Wang T; Sun L; Li X; Jiang Z; Zhang L
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1306-1320. PubMed ID: 32869445
[TBL] [Abstract][Full Text] [Related]
3. Bowman-Birk inhibitor attenuates dystrophic pathology in mdx mice.
Morris CA; Selsby JT; Morris LD; Pendrak K; Sweeney HL
J Appl Physiol (1985); 2010 Nov; 109(5):1492-9. PubMed ID: 20847128
[TBL] [Abstract][Full Text] [Related]
4. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
6. Hemojuvelin is a novel suppressor for Duchenne muscular dystrophy and age-related muscle wasting.
Zhang P; He J; Wang F; Gong J; Wang L; Wu Q; Li W; Liu H; Wang J; Zhang K; Li M; Huang X; Pu C; Li Y; Jiang F; Wang F; Min J; Chen X
J Cachexia Sarcopenia Muscle; 2019 Jun; 10(3):557-573. PubMed ID: 30884219
[TBL] [Abstract][Full Text] [Related]
7. TAK1 inhibition improves myoblast differentiation and alleviates fibrosis in a mouse model of Duchenne muscular dystrophy.
Xu D; Li S; Wang L; Jiang J; Zhao L; Huang X; Sun Z; Li C; Sun L; Li X; Jiang Z; Zhang L
J Cachexia Sarcopenia Muscle; 2021 Feb; 12(1):192-208. PubMed ID: 33236534
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
9. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice.
Freeman E; Langlois S; Leyba MF; Ammar T; Léger Z; McMillan HJ; Renaud JM; Jasmin BJ; Cowan KN
Skelet Muscle; 2024 Apr; 14(1):8. PubMed ID: 38671506
[TBL] [Abstract][Full Text] [Related]
10. p-TAK1 acts as a switch between myoblast proliferation phase and differentiation phase in mdx mice via regulating HO-1 expression.
Fan S; Huang X; Tong H; Hong H; Lai Z; Hu W; Liu X; Zhang L; Jiang Z; Yu Q
Eur J Pharmacol; 2022 Oct; 933():175277. PubMed ID: 36113553
[TBL] [Abstract][Full Text] [Related]
11. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
[TBL] [Abstract][Full Text] [Related]
12. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
14. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ
Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
16. Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model.
Roy A; Koike TE; Joshi AS; Tomaz da Silva M; Mathukumalli K; Wu M; Kumar A
JCI Insight; 2023 May; 8(10):. PubMed ID: 37071470
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
Barker RG; Wyckelsma VL; Xu H; Murphy RM
Am J Physiol Cell Physiol; 2018 Apr; 314(4):C483-C491. PubMed ID: 29351413
[TBL] [Abstract][Full Text] [Related]
19. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum brevis and interosseus muscles from the mdx mouse model of Duchenne muscular dystrophy.
Carberry S; Brinkmeier H; Zhang Y; Winkler CK; Ohlendieck K
Int J Mol Med; 2013 Sep; 32(3):544-56. PubMed ID: 23828267
[TBL] [Abstract][Full Text] [Related]
20. Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.
Capogrosso RF; Mantuano P; Uaesoontrachoon K; Cozzoli A; Giustino A; Dow T; Srinivassane S; Filipovic M; Bell C; Vandermeulen J; Massari AM; De Bellis M; Conte E; Pierno S; Camerino GM; Liantonio A; Nagaraju K; De Luca A
FASEB J; 2018 Feb; 32(2):1025-1043. PubMed ID: 29097503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
